Clinical Rheumatology

, Volume 36, Issue 1, pp 199–204 | Cite as

Severe tophaceous gout and disability: changes in the past 15 years

  • Carlos Omar López López
  • Everardo Fuentes Lugo
  • Everardo Alvarez-Hernández
  • Ingris Peláez-Ballestas
  • Rubén Burgos-Vargas
  • Janitzia Vázquez-Mellado
Brief Report


Epidemiologic data from recent decades show a significant increase in the prevalence and incidence of gout worldwide, in addition to changes in its clinical expression. Our objective was to compare the frequency of the severity of gout and disability in two patient groups at our clinic during different periods. We included and compared data of two groups: group A (1995–2000), patients from previous report, and group B (2010–2014), the baseline data of current patients participating in a cohort (GRESGO). This evaluation included data of socioeconomic and educational levels, demographics, associated diseases, previous treatment, clinical and biochemical data, and disability evaluated using the Health Assessment Questionnaire (HAQ). We included data of 564 gout patients. Participants were 35.7 ± 12.7 years old at onset and had 12.0 ± 9.2-years disease duration at their first evaluation in our department. Group B patients were younger, had higher educational and socioeconomic levels, and had more severe disease. However, this group had less frequency of some associated diseases and significantly higher HAQ scores. With increased HAQ score, a higher number of acute flares and tender, limited-to-motion, and swollen joints were seen. The spectrum of gout has changed over the past decade. A higher percentage of our patients had a severe form of disease, were younger, had earlier disease onset, and had more disability reflected in higher HAQ scores. In our current patient group, the variable most associated with disability was limited-to-motion joints; however, the number of acute flares and tender and swollen joints was also higher in patients with greater disability.


Disability Gout HAQ Tophaceous gout 



The GRESGO cohort received unrestricted, partial financial support from the Takeda Laboratories, the Dirección de Investigación of the Hospital General de México, and the Colegio Mexicano de Reumatología. We thank Maria Eugenia Sanchez Girard and Aarón Vázquez Mellado, research assistants for the GRESGO cohort.

Compliance with ethical standards




  1. 1.
    Juraschek SP, Kovell LC, Miller ER, Gelber AC (2015) Gout, urate lower therapy and uric acid levels among US adults. Arthritis Care Res 4:588–592CrossRefGoogle Scholar
  2. 2.
    Chandrate P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD (2013) Health related quality of life in gout: a systematic review. Rheumatology 52:2031–2040CrossRefGoogle Scholar
  3. 3.
    Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M (2015) Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 74:661–667CrossRefPubMedGoogle Scholar
  4. 4.
    Saag K, Choi H (2006) Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 8(Suppl 1):S2CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Arromdee E, Michet CJ, Crowson CS, O’Fallon WM, Gabriel SE (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406PubMedGoogle Scholar
  6. 6.
    Inokuchi T, Zenta T, Takahashi S, et al. (2010) Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout. J Clin Rheumatol 16:109–112CrossRefPubMedGoogle Scholar
  7. 7.
    Zampogna G, Andracco R, Parodi M, Cutolo M, Cimmino MA (2012) Has the clinical spectrum of gout changed over the last decades? Clin Exp Rheumatol 30:414–416PubMedGoogle Scholar
  8. 8.
    Perez-Ruiz F, Herrero-Beites A (2012) Changes in gout patient’s clinical profile in the last two decades. Arthritis Rheum 64(10 Suppl):S1–1216Google Scholar
  9. 9.
    Vázquez-Mellado J, Cruz J, Guzmán S, Casasola-Vargas J, Lino L, Burgos-Vargas R (2006) Severe tophaceous gout. Characterization of low socioeconomic level patients from México. Clin Exp Rheumatol 24:233–238PubMedGoogle Scholar
  10. 10.
    Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 20:895–900CrossRefPubMedGoogle Scholar
  11. 11.
    Vázquez-Mellado J, Hernández-Cuevas CB, Alvarez-Hernández E, Ventura-Rios L, Peláez-Ballestas I, Casasola-Vargas J, García-Méndez S, Burgos-Vargas R (2012) The diagnostic value of the proposal for clinical gout diagnosis (CGD). Clin Rheumatol 31:429–434CrossRefPubMedGoogle Scholar
  12. 12.
    Alvarez-Hernandez E, Pelaez-Ballestas I, Vazquez-Mellado J, et al. (2008) Validation of the health assessment questionnaire disability index in patients with gout. Arthritis Rheum 59:665–669CrossRefPubMedGoogle Scholar
  13. 13.
    Bronfman M, Guiscafre H, Castro V, Castro R, Gutierrez G (1988) La medición de la desigualdad: una estrategia metodológica, análisis de las características socioeconómicas de la muestra. Arch Invest Med 19:351–360Google Scholar
  14. 14.
    Moreno-Montoya J, Alvarez Nemegyei J, Trejo-Valdivia B, Peláez-Ballestas I (2014) Assessment of the dimensions, construct validity, and utility for rheumatoid arthritis screening of the COPCORD instrument. Clin Rheumatol 33:631–636CrossRefPubMedGoogle Scholar
  15. 15.
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97Google Scholar
  16. 16.
    Levey AS, Bosch JP, Lewis JB, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461–470CrossRefPubMedGoogle Scholar
  17. 17.
    Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, Bianchini E, Medea G, Cricelli C, Caputi AP, Mazzaglia G (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 72(5):694–700CrossRefPubMedGoogle Scholar
  18. 18.
    Khanna D, Fitzgerald JD, Khanna PP, American College of Rheumatology, et al. (2012) American College of Rheumatology guidelines for management of gout. Part I: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64:1431–1445CrossRefGoogle Scholar
  19. 19.
    Peláez-Ballestas I, Boonen A, Vázquez-Mellado J, Reyes-Lagunes I, Hernández-Garduño A, Goycochea MV, Bernard-Medina AG, Rodríguez-Amado J, Casasola-Vargas J, Garza-Elizondo MA, Aceves FJ, Shumski C, Burgos-Vargas R, REUMAIMPACT group (2015) Coping strategies for health and daily-life stressors in patients with rheumatoid arthritis, ankylosing spondylitis, and gout: STROBE-compliant article. Medicine 94(10):e600. doi: 10.1097/MD.0000000000000600 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zandman-Goddard G, Amital H, Shamrayevsky N, et al. (2013) Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology 52:1126–1131CrossRefPubMedGoogle Scholar
  21. 21.
    Scire CA, Mara M, Cimmino MA, Govoni M, Salaffi F, et al. (2013) Gout impacts on function and health-related quality life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ter 15(5):R101CrossRefGoogle Scholar
  22. 22.
    Goycochea MV, Sanin LH, Moreno J, Alvarez J, Burgos R, Garza M, et al. (2011) Validity of the COPCORD core questionnaire as a classification tool for rheumatic diseases. J Rheumatol 38:31–35Google Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2016

Authors and Affiliations

  • Carlos Omar López López
    • 1
  • Everardo Fuentes Lugo
    • 2
  • Everardo Alvarez-Hernández
    • 2
  • Ingris Peláez-Ballestas
    • 2
  • Rubén Burgos-Vargas
    • 2
  • Janitzia Vázquez-Mellado
    • 2
  1. 1.Servicio de Medicina Física y Rehabilitación, Unidad 402Hospital General de MéxicoMexico D.F.Mexico
  2. 2.Servicio de Reumatología, Unidad 404Hospital General de MéxicoMexico D.F.Mexico

Personalised recommendations